Olanzapine Actavis 20mg Orodispersible Tablets

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

现在购买

资料单张 资料单张 (PIL)
11-10-2017
产品特点 产品特点 (SPC)
11-10-2017

有效成分:

Olanzapine

可用日期:

Actavis Group PTC ehf

ATC代码:

N05AH; N05AH03

INN(国际名称):

Olanzapine

剂量:

20 milligram(s)

药物剂型:

Orodispersible tablet

处方类型:

Product subject to prescription which may not be renewed (A)

治疗领域:

Diazepines, oxazepines, thiazepines and oxepines; olanzapine

授权状态:

Marketed

授权日期:

2010-08-06

资料单张

                                PACKAGE LEAFLET: INFORMATION FOR THE USER
OLANZAPINE ACTAVIS 5 MG ORODISPERSIBLE TABLET
OLANZAPINE ACTAVIS 10 MG ORODISPERSIBLE TABLET
OLANZAPINE ACTAVIS 15 MG ORODISPERSIBLE TABLET
OLANZAPINE ACTAVIS 20 MG ORODISPERSIBLE TABLET
Olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START
TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or
pharmacist.
•
This medicine has been prescribed for you only. Do
not pass it on to others. It may harm them, even if
their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or
pharmacist. This includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1 WHAT OLANZAPINE ACTAVIS IS AND WHAT IT IS
USED FOR
2
WHAT YOU NEED TO KNOW BEFORE YOU TAKE
OLANZAPINE ACTAVIS
3
HOW TO TAKE OLANZAPINE ACTAVIS
4
POSSIBLE SIDE EFFECTS
5
HOW TO STORE OLANZAPINE ACTAVIS
6
CONTENTS OF THE PACK AND OTHER INFORMATION
1 WHAT OLANZAPINE ACTAVIS IS AND WHAT IT IS
USED FOR
Olanzapine Actavis contains the active substance
olanzapine. Olanzapine Actavis belongs to a group of
medicines called antipsychotics and is used to treat the
following conditions:
• Schizophrenia, a disease with symptoms such as hearing,
seeing or sensing things which are not there, mistaken
beliefs, unusual suspiciousness and becoming withdrawn.
People with this disease may also feel depressed, anxious
or tense.
• Moderate to severe manic episodes, a condition with
symptoms of excitement or euphoria.
Olanzapine Actavis has been shown to prevent recurrence
of these symptoms in patients with bipolar disorder whose
manic episode has responded to olanzapine treatment.
2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE
OLANZAPINE ACTAVIS
DO NOT TAKE OLANZAPINE ACTAVIS
• if you are allergic (hypersensitive) to olanzapine or any of
the other ingredients of this medicine (listed in section 6).
An allergic reaction may be recogni
                                
                                阅读完整的文件
                                
                            

产品特点

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Olanzapine Actavis 20mg Orodispersible Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each orodispersible tablet contains 20mg olanzapine.
Excipients: aspartame (E951) 11.2mg, respectively.
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Orodispersible tablet.
A round biconvex, yellow tablet 10 mm in diameter and marked with
“O3” on one side, rapid-dispersing preparation to
be placed in the mouth or alternatively to be dispersed in water or
other suitable beverage for administration.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Adults
Olanzapine is indicated for the treatment of schizophrenia.
Olanzapine is effective in maintaining the clinical improvement during
continuation therapy in patients who have
shown an initial treatment response.
Olanzapine is indicated for the treatment of moderate to severe manic
episode.
In patients whose manic episode has responded to olanzapine treatment,
olanzapine is indicated for the prevention of
recurrence in patients with bipolar disorder (see section 5.1).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults_
Schizophrenia:
The recommended starting dose for olanzapine is 10 mg/day.
Manic episode:
The starting dose is 15 mg as a single daily dose in monotherapy or 10
mg daily in combination therapy (see section
5.1).
Preventing recurrence in bipolar disorder:
The recommended starting dose is 10 mg/day. For patients who have been
receiving olanzapine for treatment of manic
episode,
continue therapy for preventing recurrence at
the same dose.
If a new manic,
mixed,
or depressive episode
occurs,
olanzapine treatment should be continued (with dose optimisation as
needed),
with supplementary therapy to
treat mood symptoms, as clinically indicated.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___

                                
                                阅读完整的文件
                                
                            

搜索与此产品相关的警报